Diploma (LON:DPLM) Reaches New 12-Month High on Analyst Upgrade

Diploma PLC (LON:DPLM) hit a new 52-week high on Thursday after Berenberg Bank raised their price target on the stock from GBX 5,750 to GBX 6,350. Berenberg Bank currently has a buy rating on the stock. Diploma traded as high as GBX 5,565 ($75.57) and last traded at GBX 5,540 ($75.23), with a volume of 239194 shares traded. The stock had previously closed at GBX 5,440 ($73.87).

Several other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 4,440 price objective on shares of Diploma in a research report on Wednesday, August 6th. Shore Capital reaffirmed a “hold” rating and issued a GBX 5,100 price objective on shares of Diploma in a research report on Thursday, July 17th. Finally, Jefferies Financial Group boosted their price objective on shares of Diploma from GBX 4,500 to GBX 5,200 and gave the company a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of GBX 5,238.

Diploma Stock Up 1.8%

The firm’s 50-day simple moving average is GBX 5,273.59 and its 200 day simple moving average is GBX 4,616.20. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The stock has a market capitalization of £7.43 billion, a P/E ratio of 4,456.96, a PEG ratio of 2.82 and a beta of 0.75.

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.